irinotecan kabi
fresenius kabi polska sp.z.o.o. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
metforal
berlin-chemie ag (menarini group) - metformino hidrochloridas - plėvele dengtos tabletės - 500 mg; 850 mg - metformin
metformin ingen pharma
sia ingen pharma - metformino hidrochloridas - plėvele dengtos tabletės - 1000 mg; 850 mg; 500 mg - metformin
tivulin
berlin-chemie ag - metformino hidrochloridas - pailginto atpalaidavimo tabletės - 500 mg - metformin
tivulin
berlin-chemie ag - metformino hidrochloridas - pailginto atpalaidavimo tabletės - 750 mg - metformin
tivulin
berlin-chemie ag - metformino hidrochloridas - pailginto atpalaidavimo tabletės - 1000 mg - metformin
bosulif
pfizer europe ma eeig - bosutinibas (kaip monohidratas) - leukemija, mieloidas - antineoplastic agents, protein kinase inhibitors - bosulif fluorouracilu gydyti suaugusiems pacientams, sergantiems:naujai diagnozuojama lėtinė fazė (cp) filadelfijos chromosoma-teigiamas lėtinės mielogeninės leukemijos (ph+ lml). cp, pagreitinto etapas (ap), ir sprogimo etapas (bp) ph+ lml anksčiau buvo elgiamasi su viena ar daugiau tirozino kinazės inhibitorius(s) [tki(ų)] ir kam imatinib, nilotinib ir dasatinib nėra tinkama gydymo galimybės.
orserdu
stemline therapeutics b.v. - elacestrant - krūties navikai - endokrininė terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
irinotecan actavis
actavis group ptc ehf. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan